(Q37155636)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Andrew N Hughes

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Mary E R O'Brien

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

W Jeffrey Petty

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Jonathan B Chick

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Elaine Rankin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

David Dunlop

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Marianne Nicolson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Ramesh Boinpally

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Julie Wolf

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Allan Price

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

language of work or name

English

0 references

publication date

21 January 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Oncology

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

1220-1226

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia

20 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667823

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667823

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667823

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667823

Erlotinib in lung cancer - molecular and clinical predictors of outcome

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667823

Erlotinib in previously treated non-small-cell lung cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667823

Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667823

Preclinical studies with Erlotinib (Tarceva).

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667823

Drug interactions with tobacco smoking. An update

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667823

Erlotinib: optimizing therapy with predictors of response?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667823

Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667823

Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667823

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667823

Effects of smoking on the pharmacokinetics of erlotinib

3 September 2018

1 reference

12 December 2020

Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer

1 reference

12 December 2020

Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21

1 reference

12 December 2020

Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

1 reference

12 December 2020

Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2008.19.3995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19164205%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

PubMed publication ID

19164205

1 reference